BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 8735796)

  • 1. Central venous access catheters in children with haemophilia.
    Blanchette VS; al-Musa A; Stain AM; Filler RM; Ingram J
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S39-44. PubMed ID: 8735796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central venous access devices for paediatric patients with haemophilia: a single-institution experience.
    Titapiwatanakun R; Moir C; Pruthi RK; Stavlo PL; Schmidt KA; Rodriguez V
    Haemophilia; 2009 Jan; 15(1):168-74. PubMed ID: 19149849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central venous access devices in children with hemophilia: an update.
    Blanchette VS; Al-Musa A; Stain AM; Ingram J; Fille RM
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S11-4. PubMed ID: 9351530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters.
    Mancuso ME; Mannucci PM; Sartori A; Agliardi A; Santagostino E
    Br J Haematol; 2008 May; 141(5):689-95. PubMed ID: 18410458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of implantable venous access devices in children with severe hemophilia: benefits and burden.
    Van Dijk K; Van Der Bom JG; Bax KN; Van Der Zee DC; Van Den Berg MH
    Haematologica; 2004 Feb; 89(2):189-94. PubMed ID: 15003894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiologic placement of a low profile implantable venous access port in a pediatric population.
    Nosher JL; Bodner LJ; Ettinger LJ; Siegel RL; Gribbin C; Asch J; Drachtman RA
    Cardiovasc Intervent Radiol; 2001; 24(6):395-9. PubMed ID: 11907746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
    Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
    Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatal central venous catheter-related infection in haemophilia.
    Crary SE; Buchanan GR; Journeycake JM
    Haemophilia; 2006 Mar; 12(2):183-6. PubMed ID: 16476095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
    Taki M; Shirahata A
    Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders.
    Komvilaisak P; Connolly B; Naqvi A; Blanchette V
    Haemophilia; 2006 Dec; 12 Suppl 6():87-93. PubMed ID: 17123400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complications of central venous access devices in paediatric haemophilia patients.
    Domm JA; Hudson MG; Janco RL
    Haemophilia; 2003 Jan; 9(1):50-6. PubMed ID: 12558778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk associated with indwelling catheters in children with haemophilia.
    Ljung R
    Br J Haematol; 2007 Sep; 138(5):580-6. PubMed ID: 17686052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A life-threatening cardiomyopathy following port-a-cath infection under immune tolerance therapy].
    Wiegand G; Rauch R; Girisch M; Hofbeck M
    Hamostaseologie; 2007 Sep; 27(4):290-2. PubMed ID: 17938769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneously implanted central venous access devices in cancer patients: a prospective analysis.
    Schwarz RE; Groeger JS; Coit DG
    Cancer; 1997 Apr; 79(8):1635-40. PubMed ID: 9118051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current status of prophylactic replacement therapy in children and adults with haemophilia.
    Ljung R; Gretenkort Andersson N
    Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
    Dodd C; Watts RG
    Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venous access in haemophilic children: choice and management.
    Santagostino E; Mancuso ME
    Haemophilia; 2010 Jan; 16 Suppl 1():20-4. PubMed ID: 20059565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.